Catheter Ablation versus Medical Therapy of Atrial Fibrillation in Patients with Heart Failure: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors:
- Michele MagnocavalloMMMichele Magnocavallo
- Antonio ParlavecchioAPAntonio Parlavecchio
- Giampaolo VettaGVGiampaolo Vetta
- Marco PolselliMPMarco Polselli
- Francesco De VuonoFVFrancesco De Vuono
- Luigi PannoneLPLuigi Pannone
- Sanghamitra MohantySMSanghamitra Mohanty
- Filippo Maria CautiFCFilippo Maria Cauti
- Rodolfo CaminitiRodolfo Caminiti
- Vincenzo MiragliaVMVincenzo Miraglia
- Cinzia MonacoCMCinzia Monaco
Open Access
- 21 September 2022
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5530
Abstract
Background: Atrial fibrillation (AF) and heart failure (HF) often coexist and synergistically contribute to an increased risk of hospitalization, stroke, and mortality. Objective: To compare the efficacy of catheter ablation (CA) versus medical therapy (MT) in HF patients with AF. Methods: Electronic databases were queried for randomized controlled trials (RCTs) of CA versus MT of AF in patients with HF. Risk ratios (RRs), mean differences (MDs), and 95% confidence intervals (CIs) were measured using the Mantel–Haenszel method. Results: A total of nine RCTs enrolling 2155 patients met the inclusion criteria. Compared to MT, CA led to a significant reduction in the composite of all-cause mortality and HF hospitalization (24.6% vs. 37.1%; RR: 0.65 (95% CI: 0.53–0.80); p < 0.0001), all-cause mortality (8.8% vs. 13.6%; RR: 0.65 (95% CI: 0.51–0.82); p = 0.0005), HF hospitalization (15.4% vs. 22.4%; (RR: 0.67 (95% CI: 0.54–0.82); p = 0.0001), AF recurrence (31.8% vs. 77.0%; RR: 0.36 (95% CI: 0.24–0.54); p < 0.0001), and cardiovascular (CV) death (4.9% vs. 8.4%; RR: 0.58 (95% CI: 0.39–0.86); p = 0.007). CA improved the left ventricular ejection fraction (MD:4.76% (95% CI: 2.35–7.18); p = 0.0001), 6 min walk test (MD: 20.48 m (95% CI: 10.83–30.14); p < 0.0001), peak oxygen consumption (MD: 3.1 2mL/kg/min (95% CI: 1.01–5.22); p = 0.004), Minnesota Living with Heart Failure Questionnaire score (MD: −6.98 (95% CI: −12–03, −1.93); p = 0.007), and brain natriuretic peptide levels (MD:−133.94 pg/mL (95% CI: −197.33, −70.55); p < 0.0001). Conclusions: In HF patients, AF catheter ablation was superior to MT in reducing CV and all-cause mortality. Further significant benefits occurred within the ablation group in terms of HF hospitalizations, AF recurrences, the systolic function, exercise capacity, and quality of life.Keywords
This publication has 37 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trialHeart, 2010
- Pulmonary-Vein Isolation for Atrial Fibrillation in Patients with Heart FailureNew England Journal of Medicine, 2008
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Risk of proarrhythmic events in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) studyJACC, 2004
- Electrical Remodeling of the Atria in Congestive Heart FailureCirculation, 2003
- Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on MortalityCirculation, 2003
- Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trialsJACC, 1998
- Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillationJACC, 1992
- Predictors of Thromboembolism in Atrial Fibrillation: I. Clinical Features of Patients at RiskAnnals of Internal Medicine, 1992